ONCONETIX INC (ONCO) Stock News
NASDAQ:ONCO - Nasdaq - US68237Q1040 - Common Stock - Currency: USD
ONCO Latest News, Press Relases and Analysis
Curious about the stocks that are showing activity after the closing bell on Thursday?
As the regular session of the US market concludes on Thursday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Top movers analysis in the middle of the day on 2025-06-11: top gainers and losers in today's session.
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders
Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders
CINCINNATI, Ohio, June 11, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology...
Analyst Reiterates Buy on Nvidia (NVDA): ‘Best Positioned in AI’
We recently published a list of 10 AI Stocks on Latest News and Ratings. In this article, we are going to take a look at where NVIDIA Corporation (NASDAQ:NVDA) stands against other best AI stocks on latest news and ratings. NVIDIA Corporation (NASDAQ:NVDA) specializes in AI-driven solutions, offering platforms for data centers, self-driving cars, robotics, […]
Onconetix receives additional delisting notice from Nasdaq
Onconetix (ONCO) received a staff delisting letter from Nasdaq on May 20 indicating that the company’s failure to file its Quarterly Report Q for the three months ended March 31, 2025 is in violation of Nasdaq’s continued listing requirements. The company received a deficiency notice from Nasdaq that the company was not in compliance with Nasdaq’s Listing Rules as set forth in the Rule given the company’s failure to timely file its Annual Report on Form 10-K for FY24. The company received a Staf
Mentions: PFBC
IAGG Attracted $1.9B Thursday as Markets Closed Flat
- IAGG led ETF inflows amid Treasury yield concerns. - International bond ETFs gained as investors diversified.
Record ETF Launches Drive Active Fund Growth in 2025
- The global ETF industry recorded 847 new product launches in first four months of 2025. - Active ETFs attracted $32.2 billion in net inflows during April alone. - JPMorgan’s Nasdaq Equity Premium Income ETF (JEPQ) led monthly inflows at $1.7 billion.
Preferred Bank announces new $125M stock repurchase plan
Preferred Bank (PFBC) reported that the shareholders have approved a new $125M stock repurchase plan. Also, on May 8, the bank completed its prior stock repurchase plan. This was the final portion of the bank’s $150M repurchase authorized by shareholders in 2023. The final tranche of repurchase activity saw the Bank repurchase 818,059 shares for total consideration of $65.7M over the first and second quarters of 2025. For the entire $150M repurchase, the bank repurchased 2,146,252 shares at an a
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
Cincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from...
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
Cincinnati, OH, April 30, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter...
Why Onconetix (ONCO) Stock Is Exploding Higher
Onconetix shares are trading higher by 85% during Tuesday's session. The company signed a non-binding letter of intent to merge with privately held Ocuvex Therapeutics.
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) (
Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress
CINCINNATI, March 19, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) (“Onconetix” or the “Company”), (formerly Blue Water Biotech, Inc....